大鼠血清表皮生长因子和睾丸表皮生长因子受体与精子生成的相关性

目的　探讨血清表皮生长因子 ( EGF)和睾丸组织表皮生长因子受体 ( EGF-R)与大鼠精子生成的关系。　方法　 40只性成熟期雄性 SD大鼠 ,随机分为假手术组( SOG)、去颌下腺组 ( SG)、去颌下腺加腹腔注射 EGF I组 ( SG-EGF I)和 II组 ( SG-EGFII) ,每组 1 0只。SG-EGF I和 SG-EGF II分别腹腔内注射 EGF0 .2 5和 0 .50 μg·kg- 1·d- 1。大鼠常规喂养 48d,断头取血和睾丸。放射免疫法检测血清 EGF水平 ,病理检查睾丸生精功能和免疫组织化学检测睾丸组织 EGF-R的表达。　结果　大鼠血清 EGF水平SG-EGF I组明显下降 ( P<0 .0 5) ,SG组有非常显著下降 ( P<0 .0 1 ) ;睾丸生精功能中、重度障碍 ;间质细胞 EGF-R表达明显减少 ( P<0 .0 5)。补充不同剂量的 EGF对睾丸生精功能有不同影响。 SOG、SG-EGF I和 SG-EGF II大鼠睾丸生精细胞、支持细胞及间质细胞 EGF-R表达无显著性差异 ( P>0 .0 5)。　结论　EGF对精子发生具重要的调控作用 ,血清 EGF水平和睾丸间质细胞 EGF-R高表达与睾丸生精功能呈正相关     

表皮生长因子在睾丸生精过程中的调节作用

表皮生长因子(Epidermal Growth Factor,EGF)是一种多肽激素,具有多种生物学活性,包括刺激各种上皮细胞的分裂与增殖。在雄性小鼠体内,大量的EGF产生于颌下腺。Tsutsumi指出EGF可能通过刺激生精发生过程中的减数分裂,而对男性生殖功能具有一种生理调节作用。我们通过对成熟与未成熟的小鼠施行颌下腺切除术,并于术后35天,对睾丸生精上皮周期中第7期与第8期的各级生精细胞进行了定量分析,结果显示未成熟小鼠在施行颌下腺切除手术后,生精上皮中各级生精细胞均少于相应的对照组;而成熟期小鼠在施行上述手术后仅A型精原细胞以后的各级生精细胞少于相应的对照组。这表明在精子发生过程中EGF不仅对减数分裂有刺激作用,而且对有丝分裂也有刺激作用。提示在控制精子发生过程中存在一个颌下腺-睾丸轴。     

无精子症及隐匿精子症患者睾丸体积与睾丸活检组织生精细胞的关系

目的:研究无精子症及隐匿精子症患者睾丸活检组织生精细胞类型及睾丸体积之间的关系。方法:收集来我院就诊的无精子症及隐匿精子症患者的完整睾丸活检病理报告,参照WHO《男性不育标准化诊疗手册》睾丸组织学分类方法进行分类,分析精液检查结果、睾丸组织学类型及睾丸体积之间的关系。结果:在492例患者中,无精子症占90.5%(445/492),隐匿精子症占9.5%(47/492)。生精小管内见成熟精子占17.9%(88/492)、生精小管内见生精细胞未见成熟精子占42.9%(211/492)、唯支持细胞综合征39.2%(193/492)。睾丸体积10ml及以下占38.6%(190/492),其中5ml及以下占7.9%(39/492)。生精小管内见成熟精子患者隐匿精子症检出率14.8%(13/88),生精小管内见生精细胞未见成熟精子患者隐匿精子症检出率11.4%(24/211),唯支持细胞综合征患者隐匿精子症检出率5.2%(10/193),唯支持细胞综合征患者隐匿精子症检出率显著下降(P<0.05)。结论:睾丸生精功能可能为局灶性,单次睾丸活检难以全面、完整反映睾丸生精功能状态。睾丸体积显著低于正常参考值仍会存在生精功能。睾丸活检适应证的掌握过于宽松。采用WHO的睾丸组织学分类方法,能更方便、更有效指导临床进一步检查及治疗方案。     

抑制素B βB亚单位在不同病理分型的无精子症患者睾丸组织中的表达

目的:探讨抑制素B(INH B)βB亚单位在不同生精功能状态的人睾丸组织中的表达情况。方法:对83例无精子症患者进行睾丸组织病理检查诊断,根据病理形态的不同分为:唯支持细胞综合征型(n=21);生精功能低下型(n=20);生精阻滞型(n=24);生精功能基本正常型(n=18)。选择上述各型结构完整的睾丸组织,分别应用免疫组化法(SP)对血清INH B βB亚单位在不同生精功能状态的睾丸组织,进行定位研究。结果:各型睾丸组织内均存在血清INH B βB的表达,其分布特点为:间质细胞(Leydig cell)和早期生精细胞多为强阳性表达,呈深棕黄色;支持细胞(Sertoli cell)多为阳性表达;而晚期精子细胞和成熟精子未见表达;生精小管管周类肌细胞呈弱阳性表达。结论:INH B可能是睾丸Sertoli细胞和早期生精细胞的一个联合产物。     

Attractin蛋白在大鼠睾丸和附睾中的免疫组织化学定位

目的 :探讨Attractin蛋白在成熟大鼠睾丸和附睾组织中的分布。　方法 :健康成年雄性SD大鼠 2 0只 ,灌流取睾丸和附睾组织固定 ,石蜡包埋和冰冻切片。用免疫组化法和间接免疫荧光方法检测Attractin蛋白在成熟大鼠睾丸和附睾组织中的表达。　结果 :睾丸组织间质细胞、睾丸精曲小管管周肌样细胞和各级生精细胞 (精原细胞、初级精母细胞和精子细胞 )、支持细胞呈阳性反应 ,主要表达于胞膜及胞质。睾丸间质细胞表达略强于生精细胞。附睾头、体、尾均未见表达。　结论 :Attractin蛋白在成熟大鼠睾丸组织间质细胞和生精细胞中有较强的表达 ,其生理功能尚有待进一步探讨。     

睾丸巨噬细胞与雄性生殖

睾丸生殖细胞包含有各种细胞,按主要功能来区分,主要分生精细胞和非生精细胞,在睾丸众多细胞中,睾丸巨噬细胞(Testicular Macrophages)作为一类非生精细胞,具有特殊功能,它除了对睾丸的内环境有免疫防御的功能,还具有分泌功能,对相邻细胞的发育、成熟等方面有重要调控作用.     

表皮生长因子和表皮生长因子受体在隐睾症男童表达的改变及其临床意义

目的:探讨表皮生长因子(EGF)及表皮生长因子受体(EGFR)在隐睾症男童的表达改变及其临床意义。方法：用放射性免疫法测定血清EGF，免疫组化法测定EGFR表达。结果(1)5—9岁及10—14岁隐睾症男童血清EGF水平显著低于正常男童(P＜0．01)，(2)腹腔隐睾症患者的血清EGF水平比腹股沟管内及腹股沟管外隐睾症患者显著为低，(3)睾丸固定术后6个月血清EGF水平显著增高(P＜0．05)，(4)2—4岁患者间质细胞中EGFR的表达显著低于5岁以上的患者(P＜0．05)，(5)腹腔隐睾症及腹股沟管内隐睾症患者的EGFR阳性表达显著低于腹股沟外隐睾症患者(P＜0．01)。结论：EGF及EGFR的表达可能和年龄及睾丸位置有关。睾丸固定术可改善隐睾症男童的EGF及EGFR的表达。     

先天性双侧输精管缺如患者睾丸组织中CFTR蛋白的表达及意义

目的通过观察中国CBAVD患者CFTR蛋白在睾丸组织中的表达水平,探讨其与睾丸生精功能之间的关系。方法免疫组化检测66例中国先天性双侧输精管缺如患者睾丸组织CFTR蛋白表达水平并对睾丸生精功能进行评分,探讨先天性双侧输精管缺如患者CFTR蛋白的表达情况以及其与睾丸生精功能的关系。结果免疫组化结果显示CFTR蛋白可表达于睾丸内支持细胞及生精上皮细胞,以细胞膜和细胞浆为主;CFTR蛋白在CBAVD患者睾丸生精上皮及支持细胞的表达以阳性和弱阳性为主,比例分别为50%(33/66)和37.87%(25/66),部分患者可见阴性表达,比例为4.54%(3/66);睾丸生精Johnsen评分7~10分的比例分别为4.45%(3/66)、40.9%(27/66)、42.42%(28/66)和12.23%(8/66)。部分患者存在生精功能障碍。CFTR蛋白在睾丸组织中的表达与生精功能强正相关性,相关系数为0.785(P<0.01)。结论BAVD患者睾丸内的CFTR蛋白表达以阳性和弱阳性为主;部分CBAVD患者存在生精功能障碍,CFTR蛋白在睾丸组织中的表达水平与生精功能存在强正相关性。     

睾丸生精功能障碍的促生精治疗

正睾丸内精子的产生主要受生殖内分泌激素的调控,高浓度睾酮(Testosterone,T)的生精上皮及支持细胞环境是精子发生的必须条件。在生理情况下,下丘脑、垂体及睾丸的内分泌激素形成完整的反馈调控系统,促进和调控精子的发生、成熟[1]。睾丸生精功能障碍是指因各种原因导致睾丸内生精上皮(或生精组织)生精能力下降,生精细胞部分或全部发育阻滞,形成少精子或无精子,导致男性不育。目前临床对睾丸生精功能障碍的治疗方法主要包括药物治疗、手术治疗和辅助生殖。药物治疗在临床上被广泛使用,某些药物也确实     

不同剂量己烯雌酚对新生小鼠睾丸表皮生长因子及受体的影响

目的 观察不同剂量己烯雌酚(DES)对新生小鼠睾丸组织中表皮生长因子(EGF)及其受体(EGFR)的影响,探讨DES对睾丸发育影响的机制.方法 建立小鼠DES模型.将72只怀孕的雌性昆明小鼠随机分成3组:正常组、对照组及实验组1～4(DES 10、25、50、100 μg/kg).采用免疫组织化学方法检测各组新生小鼠睾丸组织中EGF、EGFR的表达.结果 EGF和EGFR主要表达在新生小鼠睾丸的间质细胞.实验组1～4中EGF阳性细胞的累积吸光度值(IA)分别为75.43±1. 42、52.22±5.67、13.75±3.14、6.38±3.20,显著低于正常组及对照组中阳性细胞的IA值433.88±11.64、23.44±4.70;实验组EGFR阳性细胞的IA值分别为198.16±34.35、138.00±12.04、46.03±6.74、27.22±5.52,显著低于正常组及对照组中阳性细胞的IA值804.74±22.52、800.03±21.96.两者在正常、不同剂量DES实验组的两两比较差异有统计学意义(P＜0.05).随DES剂量增加,EGF和EGFR表达减弱,各组间差异有统计学意义(P＜0.05).EGF与EGFR呈强正线性相关(r=0.750,P＜0.01).结论 不同剂量DES对新生小鼠睾丸组织中EGF和EGFR表达强度均有影响,可能是影响睾丸发育机制之一.

Abstract：

Objective To investigate the effects of prenatal exposure to diethylstilbestrol (DES)with different dosages on epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR) in offspring mice testis, and the possible mechanism. Methods DES model was induced in mice by DES.Female Kungmiag mice were randomly divided into normal group, control group and experimental groups 1-4 ( DES 10, 25, 50, 100 μg/kg). Immunohistochemistry was applied to detect the expression of EGF and EGFR in the testicular tissue in each group. Results EGF and EGFR were expressed mainly in sffspring mice testis Leydig cells. The cumulative absorbance ( IA ) values of EGF positive cells in experimental groups 1-4 were 75. 43 ± 1.42, 52. 22 ± 5.67, 13.75 ± 3. 14, and 6. 38 ± 3.20 respectively, which were significantly lower than in normal and control groups (433.88 ± 11.64,423.44 ±4. 70 respectively).The IA values of EGFR positive cells in experimental groups 1-4 were 198. 16 ± 34. 35, 138.00 ± 12.04,46.03 ± 6. 74, 27.22 ± 5.52 respectively, which were significantly lower than in normal and control groups (804. 74 ± 22. 52,800. 03 ± 21.96 respectively). The expression levels of EGF and EGFR could be detected in each subgroup and statistically significant differences existed in the expression of EGF and EGFR between any two groups ( P ＜ 0. 05 ). With the increase of DES dosage, the expression of EGF and EGFR was decreased, with the difference being significant amond the groups ( P ＜ 0. 05 ). Conclusion DES can influence the expression of EGF and EGFR in mice testis, which might be one of possible mechanisms effecting the development of testis.     

膀胱移行细胞癌表皮生长因子及其受体表达和意义

目的 探讨表皮生长因子(EGF)、EGF受体(EGFR)在膀胱移行细胞癌(BTCC)中的表达及意义。方法 用免疫组化ABC法对56例BTCC标本和20例癌旁组织EGF、EGFR进行研究。结果 20例癌旁正常膀胱组织中EGF，EGFR几乎不表达；56例ETCC标本中EGF，EGFR表达明显，与正常组比较有显著性差异(P＜0．01)，不同分期和分级BTCC中的阳性表达率均存在显著性差异(P＜0．05)。结论 EGF，EGFR的检测可以作为判断BTCC预后的一个指标。     

Plasmin-induced smooth muscle cell proliferation requires epidermal growth factor activation through an extracellular pathway

BACKGROUND: Plasminogen activators are used routinely for thrombolysis. They lead to the generation of the protease, plasmin, which can induce smooth muscle cell proliferation and may thus promote further intimal hyperplasia in the thrombolysed vessel. We have shown recently that plasmin induces extracellular signal-regulated kinase 1/2 (ERK1/2)-mediated cell proliferation. Plasmin can also activate metalloproteinases on the cell surface, which can release the tethered ligand heparin-binding epidermal growth factor (HB-EGF), which can in turn activate the epidermal growth factor receptor (EGFR). METHODS: Murine aortic smooth muscle cells were cultured in vitro. Assays of DNA synthesis and cell proliferation, EGFR phosphorylation, and ERK1/2 activation were examined in response to plasmin in the presence and absence of the plasmin inhibitors (epsilon-aminocaproic acid and aprotinin), matrix metalloproteinase (MMP) inhibitor GM6001, HB-EGF inhibitor CRM197, HB-EGF inhibitory antibodies, EGF inhibitory antibodies, and the EGFR inhibitor AG1478. RESULTS: Plasmin-induced smooth muscle cell DNA synthesis, which was blocked by EGFR and HB-EGF inhibition. Plasmin-induced time-dependent EGFR phosphorylation and ERK1/2 activation, which were inhibited by AG1478. This response was dependent on the proteolytic activity of plasmin since both plasmin inhibitors blocked the response. EGFR phosphorylation by plasmin was blocked by inhibition of MMP activity and the ligand HB-EGF. EGFR phosphorylation by EGF was not interrupted by inhibition of plasmin, MMPs, or HB-EGF. Direct blockade of the EGFR prevented activation by both plasmin and EGF. CONCLUSIONS: Plasmin can induce smooth muscle cell proliferation through activation of EGFR by an extracellular MMP-mediated, HB-EGF-dependent process.     

Lidocaine Inhibits Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor and Suppresses Proliferation of Corneal Epithelial Cells

Background: Although lidocaine is recognized as an excellent topical corneal analgesic, its toxic effect on corneal epithelial cells limits its use during corneal epithelial wound healing. Mechanism of the impairment of corneal reepithelialization with lidocaine, however, has not been evaluated. The authors' previous study revealed that lidocaine inhibits the activity of tyrosine kinase receptors through the interaction with specific amino acid sequences around autophosphorylation sites, including acidic, basic, and aromatic amino acids. Epidermal growth factor receptor (EGFR), a tyrosine kinase receptor with an important role in epithelial cell proliferation after corneal wounding, also possesses these amino acids sequences around autophosphorylation sites. The authors hypothesized that lidocaine would suppress tyrosine kinase activity of EGFR and would impair corneal epithelial cell proliferation.

Methods: To investigate the effect of lidocaine (4 [mu]M-40 mM) on epidermal growth factor (EGF)-stimulated autophosphorylation of EGFR, the authors studied purified EGFR in microtubes. They cultured human corneal epithelial cells (HCECs) with EGF and lidocaine to investigate the effect of lidocaine on cell proliferation and on autophosphorylation of EGFR in HCECs.

Results: Lidocaine (>= 400 [mu]M) significantly suppressed EGF-stimulated autophosphorylation of the purified EGFR. In the HCEC study, EGF alone stimulated cell proliferation and increased autophosphorylation of EGFR in HCECs. Lidocaine (>= 400 [mu]M) significantly suppressed both the proliferation of HCECs promoted by EGF and EGF-stimulated autophosphorylation of EGFR.     

Lidocaine inhibits tyrosine kinase activity of the epidermal growth factor receptor and suppresses proliferation of corneal epithelial cells

BACKGROUND: Although lidocaine is recognized as an excellent topical corneal analgesic, its toxic effect on corneal epithelial cells limits its use during corneal epithelial wound healing. Mechanism of the impairment of corneal reepithelialization with lidocaine, however, has not been evaluated. The authors' previous study revealed that lidocaine inhibits the activity of tyrosine kinase receptors through the interaction with specific amino acid sequences around autophosphorylation sites, including acidic, basic, and aromatic amino acids. Epidermal growth factor receptor (EGFR), a tyrosine kinase receptor with an important role in epithelial cell proliferation after corneal wounding, also possesses these amino acids sequences around autophosphorylation sites. The authors hypothesized that lidocaine would suppress tyrosine kinase activity of EGFR and would impair corneal epithelial cell proliferation. METHODS: To investigate the effect of lidocaine (4 microM-40 mM) on epidermal growth factor (EGF)-stimulated autophosphorylation of EGFR, the authors studied purified EGFR in microtubes. They cultured human corneal epithelial cells (HCECs) with EGF and lidocaine to investigate the effect of lidocaine on cell proliferation and on autophosphorylation of EGFR in HCECs. RESULTS: Lidocaine (> or =400 microM) significantly suppressed EGF-stimulated autophosphorylation of the purified EGFR. In the HCEC study, EGF alone stimulated cell proliferation and increased autophosphorylation of EGFR in HCECs. Lidocaine (> or = 400 microM) significantly suppressed both the proliferation of HCECs promoted by EGF and EGF-stimulated autophosphorylation of EGFR. CONCLUSION: Lidocaine directly inhibits tyrosine kinase activity of EGFR and suppresses the corneal epithelial cell proliferation.     

Changes in epidermal growth factor receptor expression in human bladder cancer cell lines following interferon-alpha treatment

PURPOSE: We examined the regulation of epidermal growth factor (EGF) receptor (EGFR) expression in human bladder cancer cell lines by interferon-alpha (IFN-alpha), the ability of IFN-alpha to inhibit cell proliferation and the sensitivity of IFN-alpha pretreated cells to EGF. MATERIALS AND METHODS: Cell proliferation was determined using crystal violet colorimetric and clonogenic assays. EGFR expression was measured by flow cytometry using specific antibody or ligand binding approaches. RESULTS: After IFN-alpha (100 IU/ml) treatment cell surface EGFR expression was upregulated in 6 of 11 and down-regulated in 2 of 11 bladder cancer cell lines. The over expression of cell surface EGFR peaked within 48 to 96 hours and increased by 35% to 241% in individual cell lines. High level cell surface EGFR correlated with intracellular EGFR expression. Cell growth inhibition by IFN-alpha coexisted with EGFR over expression in the 6 lines. IFN-alpha treated cells remained sensitive to EGF treatment. CONCLUSIONS: IFN-alpha transiently up-regulates EGFR expression and inhibits in vitro growth in some human bladder cancer cells. IFN-alpha does not prevent EGFR from binding EGF or signal transduction via the EGF-EGFR pathway. This may have clinical implications for improving treatment based on EGFR targeting in select patients with bladder cancer.     

The role of superoxide anion in the regulation of epidermal growth factor or the expression and proliferation of its receptor in prostate cancer cell line PC3

The purpose of this study was to investigate the role of superoxide anion(O2-) in the regulation of epidermal growth factor (EGF) or epidermal growth factor receptor (EGFR) expression and proliferation in the prostate cancer cell line PC3. Cell proliferation was tested by a 3-(4,5-dimethylthiazol-2-yl)-diphenyltetrazolium bromide (MTT) assay in the presence of O2-, EGF or their combination. Immunohistochemistry was carried out to assay the expression of EGF or EGFR. EGF or EGFR mRNA expression in the cells treated with O2- was examined by in situ hybridisation. The proliferation was significantly inhibited by O2- in a concentration-dependent manner ranging from 9 to 36 micromol/l nicotinamide adenine dinucleotide (NADH) combined with 2-8 micromol/l N-methylphenazonium methyl sulfate (PMS). The enhancement of proliferation induced by 5 ng/ml EGF was significantly overcome by O2-. Although O2- was not able to alter EGFR mRNA expression, O2- at the concentration of 18 micromol/l NADH and 4 micromol/l PMS reduced EGFR protein expression. O2- at the concentration of 18 micromol/l NADH and 4 micromol/l PMS can downregulate EGF and EGF mRNA expression.     

Augmentation of 5-fluorouracil cytotoxicity by epidermal growth factor in a newly established human signet-ring cell carcinoma of the stomach in culture

A cell line designated TSG6 was established from a signet-ring cell gastric carcinoma developed in a 57-year-old female patient. The TSG6 cells had well preserved the features of signet-ring cell carcinoma based on morphology. The cells exhibited both epidermal growth factor (EGF) and epidermal growth factor receptor (EGFR) immunoreactivities, and also secreted EGF. Moreover, the growth of TSG6 cells was stimulated in the presence of exogenous EGF. These results suggest that the possible presence of an EGF/EGFR autocrine growth mechanism is expressed in the TSG6 cells. The simultaneous treatment with EGF and 5-fluorouracil (5-FU) produced a nearly 2.4-fold enhancement of 5-FU cytotoxicity against TSG6 cells. A bromodeoxyuridine/DNA How cytometry analysis revealed that EGF augmented 5-FU cytotoxicity by inducing the accumulation of S phase cells which might be more susceptible to 5-FU. Moreover, we found that the incorporation of 5-FU into the TSG6 cells was increased with the addition of EGF. These data indicate that EGF may be a potent agent as a biological response modifier for 5-FU against the tumors which express the EGF/EGFR autocrine mechanism, and that the TSG6 cell line is useful in furthering our understanding of the interaction between anticancer drugs and EGF.     

表皮生长因子和干细胞因子对小鼠生精细胞增殖与分化的作用

目的:观察表皮生长因子(EGF)和干细胞因子(SCF)体外促小鼠生精细胞增殖、分化的效应。方法:对7~8日龄雄性昆明小鼠生精细胞进行混合细胞体外培养,在培养液中分别添加不同浓度(5、10、20、40、100 ng/ml)的EGF和SCF,并进行EGF和SCF的交互实验,观察生精细胞的存活率和形态学变化,并对粗线期精母细胞特异性磷蛋白基因(P19)、单倍体精子细胞特异性转化蛋白基因(TP1)及染色体倍性进行检测。结果:加入EGF或SCF 2~4 d,各组均可见不同程度的细胞增殖,细胞呈团或族状,以20 ng/ml EGF组和40 ng/ml SCF组最为明显;培养第7天,单一添加20 ng/ml EGF或40 ng/ml SCF组生精细胞数和存活率显著高于与其它各组(P0.05),且40 ng/ml SCF组P19/TP1基因表达显著低于其它各组,单倍体细胞率显著高于其它各组(P0.05)。EGF与SCF配伍时,可显著增加体外培养后生精细胞数(P0.05)。结论:在混合生精细胞体外培养体系中,添加一定浓度的EGF和SCF可显著提高生精细胞数和存活率,而且SCF可提高单倍体精子的形成率;两者交互实验时,对细胞增殖有一定的叠加效应。     

Inhibition of chemomigration of a human prostatic carcinoma cell (TSU-pr1) line by inhibition of epidermal growth factor receptor function

Chemoattractants expressed at bony sites and pelvic lymph nodes are thought to promote the preferential metastasis of human prostate tumor cells to these organs. Epidermal growth factor (EGF) is a potent chemoattractant for several human metastatic prostate tumor cell lines, including the TSU-pr1 cell line, and EGF has been localized to the stroma of both bony sites and pelvic lymph nodes in humans. Hence, we investigated whether the TSU-pr1 cell line expresses a functional EGF receptor (EGFR), which when antagonized reduces EGF-mediated chemomigration of this cell line. In this context, the EGFR immunoprecipitated from cell lysates of TSU-pr1 cells comigrated with the EGFR from A431 cells at a molecular weight of 170 kD. Addition of human EGF (hEGF) to the TSU-pr1 cells for 5 min stimulated the dose-dependent biphasic phosphorylation of the EGFR, with maximal stimulation of EGFR phosphorylation occurring at 2 ng/ml hEGF. In addition, treatment of hEGF-stimulated (2 ng/ml) TSU-pr1 cells with 0.5 μg/ml anti-hEGFR monoclonal antibody or 100 nM staurosporine inhibited EGFR phosphorylation. Conversely, as negative controls, treatment of hEGF-stimulated (2 ng/ml) TSU-pr1 cells with K252a or dimethyl sulfoxide (DMSO) vehicle did not inhibit EGFR phosphorylation. TSU-pr1 cells were stimulated to migration in 4 hr across Boyden chambers in response to 10 ng/ml hEGF. Treatment of the TSU-pr1 cells with anti-hEGFR monoclonal antibody inhibited in a dose-dependent manner the chemomigration of the TSU-pr1 cells across Boyden chambers. Similarly, treatment of the TSU-pr1 cells with staurosporine inhibited in a dose-dependent manner the chemomigration of the TSU-pr1 cells across Boyden chambers. These results demonstrate that antagonists of hEGF-mediated hEGFR phosphorylation also antagonize chemomigration of the TSU-pr1 cells across Boyden chambers, suggesting that antagonists of the EGFR in prostate cancer may be useful in the treatment of metastatic disease. © 1996 Wiley-Liss, Inc.     

ZD1839对胰腺癌细胞的生长抑制作用及机理

目的 探讨ZD1839对胰腺癌细胞的生长抑制作用机理.方法 应用MTT方法检测ZD1839对胰腺癌细胞的生长抑制作用、应用不同的生长因子刺激胰腺癌细胞的生长刺激,并检测ZD1839对不同生长因子作用的影响.应用western blot检测不同生长因子对EGF酪氨酸激酶受体的磷酸化作用,以及ZD1839对EGFR受体磷酸化的影响,并检测ZD1839对EGFR信号的下游MAPK磷酸化的影响.结果 ZD1839呈剂量依赖性抑制胰腺癌细胞的生长,ZD1839阻断EGF对胰腺癌细胞的生长刺激作用,但不阻断对IGF-1的作用.ZD1839抑制了基础的与EGF诱导的EGF受体磷酸化水平与MAPK的磷酸化水平.结论 结果表明,EGF对胰腺癌细胞有生长刺激作用,ZD1839对胰腺癌细胞的生长抑制作用是通过对抑制EGF受体磷酸化而特异性起作用的.